SOURCE: Geneart AG

April 24, 2008 01:10 ET

The US National Cancer Institute Extends its Contract with GENEART - Order Volume USD 1.9M

REGENSBURG, GERMANY--(Marketwire - April 24, 2008) -


- The US  National Cancer  Institute (NCI)  as part  of the  National
Institutes of Health (NIH) continues its collaboration with GENEART
- The contract extension comprises a  volume of ca. USD 1.9M for  the
synthesis of more than 200 genes
- Within the scope of the ongoing contract, GENEART already  produced
more than 3,500 genes amounting to ca. USD 3.5M
-  GENEART  synthesizes  these  genes  for  the  NIH  Mammalian  Gene
Collection Program

Regensburg, April 24, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology, today announces the continuation of the collaboration with the US National Cancer Institute, which is part of the NIH. The contract was awarded and extended by SAIC Frederick, Inc. on behalf of the NCI. Within the scope of the ongoing contract, GENEART has already produced more than 3,500 genes with an order volume of about USD 3.5M. The follow-up order comprises a volume of USD 1.9M for the synthesis of another 200 highly complex genes. With the genes synthesized by GENEART, the NCI complements the NIH "Mammalian Gene Collection (MGC) Program". This comprehensive collection of human and mouse genes represents a significant resource for basic research as well as for clinical research and development.

The 3,500 genes so far synthesized by GENEART include a large number of highly complex sequences, which could not be isolated with classical methods of biotechnology in the course of the MGC project between 2002 and 2006. A major fraction of genes in this group showed a high number of repetitive DNA sequence elements, or were toxic for the production host E. coli. To efficiently synthesize this large number of genes in a high-throughput manner, GENEART had to further advance its existing technologies and establish new production techniques.

Professor Dr. Ralf Wagner, CSO of the GENEART AG, adds: "The advancements in technology have elevated our gene synthesis platform to a new level, and further strengthen our leadership role in this market. We therefore expect to profit far more than average from the increasing demand for complex genes, gene clusters and entire genomes in pharmaceutical research and in the synthetic biology field."

Christian Ehl, CFO of the GENEART AG, elaborates: "This order has been the greatest challenge in our company history so far, and we have mastered it with great success. Our performance demonstrates the capability of our team, and it proves the power of the GENEART Technology Platform. We are especially delighted about the extended collaboration with NCI because it confirms our ability to perform. Additionally, the NCI/NIH project provides us with a singular reference in the field. This will certainly help us to acquire more major projects in the global market."


For further inquiries, please contact:

Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.


About GENEART AG

In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.


About the NIH

The National Institutes of Health (NIH) ¿ The Nation's Medical Research Agency ¿ is comprised of 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The project has been funded in whole with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Service, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.


http://hugin.info/136633/R/1212577/251732.pdf



Copyright © Hugin AS 2008. All rights reserved.

Contact Information